Cardiff Lexington (CDIX) AI Stock Analysis

• Market Cap: $29.52M
• Dividend Yield: N/A
• Average Volume (3M): 18.00
• Price to Earnings (P/E): ―
• Beta (1Y): -1.07
• Revenue Growth: 9.43%
• EPS Growth: -100.25%
• Country: US
• Employees: 15
• Sector: Healthcare
• Sector Strength: 45
• Industry: Asset Management
• EPS (TTM): -0.08
• Shares Outstanding: 19,682,213
• 10 Day Avg. Volume: 20
• 30 Day Avg. Volume: 18
• PEG Ratio: 0.11
• Price to Book (P/B): 4.67
• Price to Sales (P/S): 4.29
• P/FCF Ratio: -6.17
• Enterprise Value/Market Cap: 6.29
• Enterprise Value/Revenue: 18.25
• Enterprise Value/Gross Profit: 31.43
• Enterprise Value/Ebitda: 205.86
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 51 Neutral
• Price Target: ―

Cardiff Lexington faces significant financial headwinds with declining revenues and cash flow issues. While technical analysis shows some positive momentum, the stock is potentially overbought, which could lead to a correction. The low P/E ratio may present a valuation opportunity, but the absence of a dividend yield and earnings call data limits additional insights. Overall, the stock is moderately attractive, with considerable risks that need to be addressed.

Cardiff Lexington Business Overview & Revenue Model

Company Description

Cardiff Lexington (CDIX) is a diversified holding company that primarily focuses on acquiring and managing a portfolio of small to mid-sized companies across various sectors including healthcare, real estate, and consumer products. The company aims to create value by leveraging its expertise in operational management and strategic growth initiatives to enhance the performance of its subsidiaries.

How the Company Makes Money

Cardiff Lexington makes money through its diversified portfolio of subsidiaries, each contributing to the company's overall revenue. The company generates income by acquiring profitable businesses and optimizing their operations, thereby increasing their value and cash flows. Key revenue streams include income from healthcare services, rental income from real estate properties, and sales of consumer products. Additionally, Cardiff Lexington may engage in strategic partnerships or joint ventures that further expand its market reach and revenue potential.

Cardiff Lexington Financial Statement Overview

Summary

Cardiff Lexington is experiencing significant financial challenges, including declining revenues, increasing losses, and worsening cash flows. The company faces high leverage and reduced equity, which pose substantial risks to financial stability. Negative profitability metrics further highlight the need for strategic adjustments to improve financial health.

Income Statement

The income statement shows declining revenue and profitability. Gross profit margin decreased from 70% in 2023 to 53% in 2024, and net profit margin turned from positive 25.6% to negative 51.6% in 2024. Revenue dropped by 30.2% from 2023 to 2024, indicating significant challenges in maintaining top-line growth.

Balance Sheet

The balance sheet indicates high leverage with a debt-to-equity ratio of 1.98 in 2024, up from 0.96 in 2023. The equity ratio decreased from 31.9% to 20.5% over the same period, reflecting increased financial risk. However, the return on equity turned negative due to negative net income, raising concerns about shareholder value.

Cash Flow

Cash flow analysis reveals a deteriorating situation, with negative operating cash flow worsening to -$5.86M in 2024 from -$1.72M in 2023. The free cash flow remains negative, with a substantial decline in the free cash flow to net income ratio, indicating poor cash conversion and liquidity concerns.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	10.18M	8.27M	11.85M	10.69M	9.88M	3.45M
Gross Profit	5.91M	4.43M	8.29M	6.63M	6.11M	1.78M
EBITDA	902.45K	-107.90K	5.23M	3.41M	2.67M	-1.37M
Net Income	-4.57M	-3.30M	3.03M	-5.43M	666.29K	-2.84M
Balance Sheet
Total Assets	26.51M	23.93M	20.75M	13.35M	11.16M	4.93M
Cash, Cash Equivalents and Short-Term Investments	559.72K	1.19M	866.94K	226.80K	595.99K	279.31K
Total Debt	13.58M	9.72M	6.36M	3.94M	2.98M	3.97M
Total Liabilities	25.76M	16.32M	14.12M	14.82M	8.38M	13.05M
Stockholders Equity	753.60K	7.60M	6.62M	-1.47M	2.78M	-8.12M
Cash Flow
Free Cash Flow	-6.90M	-5.75M	-1.72M	-1.14M	-1.04M	-948.01K
Operating Cash Flow	-6.90M	-5.75M	-1.72M	-1.14M	-1.04M	-948.01K
Investing Cash Flow	0.00	0.00	0.00	3.27M	-2.32M	0.00
Financing Cash Flow	4.27M	6.07M	2.37M	788.79K	3.68M	1.15M

Cardiff Lexington Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CDIX, the sentiment is Negative. The current price of 1.5 is below the 20-day moving average (MA) of 2.21, below the 50-day MA of 2.31, and below the 200-day MA of 4.56, indicating a bearish trend. The MACD of -0.40 indicates Positive momentum. The RSI at 40.93 is Neutral, neither overbought nor oversold. The STOCH value of 49.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CDIX.

Cardiff Lexington Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RMCO	54 Neutral	$50.06M	-201.18	-1.93%	0.15%	191.89%	90.32%
TURN	52 Neutral	―	―	―	―	51.84%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CDIX	51 Neutral	$29.52M	-4.20	-55.42%	―	9.43%	-100.25%
MGLD	47 Neutral	$43.67M	―	-23.47%	―	-8.17%	-39.27%
BCG	45 Neutral	$24.57M	-13.17	-11.08%	―	-27.89%	51.00%